The expression and clinical significance of placental growth factor in bone marrow specimens of multiple myeloma
-
摘要: 目的: 研究胎盘生长因子(PLGF)及骨髓微血管密度(MVD)在多发性骨髓瘤(MM)骨髓活检组织中的表达情况及临床意义。方法: 应用免疫组织化学染色方法检测40例MM患者及10例正常者骨髓活检组织PLGF及MVD的表达情况,电脑采集图像并使用Image Pro Plus6.0软件分析结果。结果: 与正常者骨髓活检组织比较,MM患者骨髓活检组织的PLGF及MVD表达显著升高(均P<0.05);在MM患者中低血红蛋白者的MVD表达较高血红蛋白者显著升高(P<0.05),但在MM分期、分型、溶骨性损害、年龄之间均差异无统计学意义。结论: PLGF及MVD在骨髓瘤较正常骨髓组织表达明显增多,骨髓血管增多在MM的发病中起到重要作用。Abstract: Objective: To explore the expression and clinical significance of the placental growth factor (PLGF) and microvessel density (MVD) in multiple myeloma (MM).Method: We analyzed the expression of PLGF and MVD in bone marrow specimens of 40 patients who diagnosed as MM and 10 normal controls,which were disposed with immunohistochemical method,the pictures were obtained by computer and analyzed by software.Result: In comparison with normal bone marrow specimens,the expression of PLGF and MVD in bone marrow from MM patients was significant increased (P<0.05).MVD showed a higher level in the patients whose hemoglobin was lower than 85 g/L (P<0.05),but there was no significant difference of MVD among different age,osteolytic lesions,type of monoclonal protein and clinical stage.Conclusion: PLGF and MVD are increased in MM,and bone marrow angiogenesis plays a notable role in MM.
-
Key words:
- placental growth factor /
- myeloma /
- immunohistochemical
-
-
[1] De Falco S.The discovery of placenta growth factor and its biological activity[J].Exp Mol Med,2012,44:1-9.
[2] Dewerchin M,Carmeliet P.PIGF:a multitasking cytokine with disease-restricted activity[J].Cold Spring Harb Perspect Med,2012,2:a011056.
[3] 张彦,孟繁军,颜学申,等.胎盘生长因子在多发性骨髓瘤中的表达及临床意义[J].临床血液学杂志,2015,28(5):416-418.
[4] 张之南,沈悌.血液病诊断和疗效标准[M].2版.北京:科学出版社,1998:373-380.
[5] Gacche RN,Meshram RJ.Angiogenic factors as potential drug target:efficacy and limitations of anti-angiogenic therapy[J].Biochim Biophys Acta,2014,1846:161-179.
[6] Tarallo V,De Falco S.The vascular endothelial growth factors and receptors family:Up to now the only target for anti-angiogenesis therapy[J].Int J Biochem Cell Biol,2015,64:185-189.
[7] Ríos-Tamayo R,Sánchez MJ,Puerta JM,et al.Trends in survival of multiple myeloma:a thirty-year population-based study in a single institution[J].Cancer Epidemiol,2015,39:693-699.
[8] Ribatti D,Mangialardi G,Vacca A.Antiangiogenic therapeutic approaches in multiple myeloma[J].Curr Cancer Drug Targets,2012,12:768-775.
[9] Dewerchin M,Carmeliet P.Placental growth factor in cancer[J].Expert Opin Ther Targets,2014,18:1339-1354.
[10] Voron T,Marcheteau E,Pernot S,et al.Control of immune response by pro-angiogenic factors[J].Front Oncol,2014,4:70.
[11] Martinsson-Niskanen T,Riisbro R,Larsson L,et al.Monoclonal antibody TB-403:a first-in-human,Phase I,double-blind,dose escalation study directed against placental growth factor in healthy male subjects[J].Clin Ther,2011,33:1142-1149.
[12] Heindryckx F,Coulon S,Terrie E,et al.The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model[J].J Hepatol,2013,58:319-328.
[13] Bais C,Wu X,Yao J,et al.PIGF blockade does not inhibit angiogenesis during primary tumor growth[J].Cell,2010,141:166-177.
-
计量
- 文章访问数: 136
- PDF下载数: 84
- 施引文献: 0